|
0
|
|
Pharmacokinetics/pharmacodynamics of KSP-1007 in combination with meropenem against carbapenemase-producing gram-negative bacteria in a neutropenic murine thigh infection model.
(journals.asm.org)
|
Takemoto K
…
Hanaki H
Antimicrobial Agents and Chemotherapy
2026-04-01
|
#pharmacokinetics
#modeling
#infection
#amr
#pharmacodynamics
|
|
0
|
|
Pharmacodynamic evaluation of BRII-693, a next-generation synthetic macrocyclic peptide antibiotic, in the neutropenic mouse thigh and lung infection models against gram-negative pathogens.
(journals.asm.org)
|
Lepak AJ
…
Andes DR
Antimicrobial Agents and Chemotherapy
2026-04-01
|
#infection
#amr
#pharmacodynamics
#antibiotic
#peptide
|
|
0
|
|
Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing Klebsiella pneumoniae in the hollow fiber infection model.
(journals.asm.org)
|
Singh N
…
Bulman ZP
Antimicrobial Agents and Chemotherapy
2026-04-01
|
#infection
#amr
#pharmacodynamics
#synergy
|
|
0
|
|
LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.
(nature.com)
|
Mabrouk OS
…
Graham DL
Nature Medicine
2026-04-01
|
#clinical trial
#pharmacodynamics
#neurodegeneration
#antisense
#neuropathology
|
|
0
|
|
Avoiding resistance development to newer drugs: open research lines.
(linkinghub.elsevier.com)
|
Rinaldi M
…
Giannella M
Clinical Microbiology and Infection
2026-04-01
|
#amr
#vaccination
#pharmacodynamics
#phage
|